[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]

G Arnold; A Kupsch

doi:10.1007/s001150050011

[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]

Nervenarzt. 2000 Feb;71(2):78-83. doi: 10.1007/s001150050011.

[Article in German]

Authors

G Arnold¹, A Kupsch

Affiliation

¹ Neurologische Klinik und Poliklinik, Universitätsklinikum Charité, Humboldt-Universität Berlin. [email protected]

PMID: 10703007
DOI: 10.1007/s001150050011

Abstract

Registration of the inhibitor of the catechol-O-methyltransfersase (COMT) tolcapone has been stopped due to the possible relationship of tolcapone treatment to three cases of fatal hepatitis. As a result, strong uncertainty has emerged among neurologists about the principle of COMT inhibition itself. We review data, especially on the remaining COMT inhibitor, entacapone, with regard to pre-clinical and clinical efficacy and safety.

Publication types

Review

MeSH terms

Antiparkinson Agents / adverse effects
Antiparkinson Agents / therapeutic use*
Benzophenones / adverse effects
Benzophenones / therapeutic use
Catechol O-Methyltransferase / physiology
Catechol O-Methyltransferase Inhibitors*
Catechols / adverse effects
Catechols / therapeutic use*
Clinical Trials as Topic
Dopamine / physiology*
Humans
Nitriles
Nitrophenols
Parkinson Disease / drug therapy*
Parkinson Disease / enzymology
Tolcapone

Substances

Antiparkinson Agents
Benzophenones
Catechol O-Methyltransferase Inhibitors
Catechols
Nitriles
Nitrophenols
entacapone
Tolcapone
Catechol O-Methyltransferase
Dopamine